Table 1.
FDA-approved monoclonal antibodies of lymphoid malignancies
| Antibody | Brand name | Type | Approval year | Target | Malignancies |
|---|---|---|---|---|---|
| Rituximab | Rituxan, mabthera | Chimeric | 1997 | CD20 | B-NHL |
| Alemtuzumab | Campath | Humanized | 2001 | CD52 | CLL |
| Ofatumumab | Arzerra | Human | 2009 | CD20 | CLL |
| I131-tositumomab | Bexxar | Murine | 2003 | CD20 | B-NHL |
| Y90-ibritumomab tiuxetan | Zevalin | Murine | 2002 | CD20 | B-NHL |
| Brentuximab vedotin | Adcetris | Chimeric | 2011 | CD30 | ALCL, HL |
Abbreviations: ALCL, anaplastic large cell lymphoma; B-NHL, B-cell non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma.